Does 3-day course of oral amoxycillin benefit children of non-severe pneumonia with wheeze: a multicentric randomised controlled trial
Shally Awasthi, Girdhar Agarwal, Sushil K Kabra, Sunit Singhi, Madhuri Kulkarni, Vaishali More, Abhimanyu Niswade, Raj Mohan Pillai, Ravi Luke, Neeraj M Srivastava, Saradha Suresh, Valsan P Verghese, P Raghupathy, R Lodha, Stephen D Walter, Shally Awasthi, Girdhar Agarwal, Sushil K Kabra, Sunit Singhi, Madhuri Kulkarni, Vaishali More, Abhimanyu Niswade, Raj Mohan Pillai, Ravi Luke, Neeraj M Srivastava, Saradha Suresh, Valsan P Verghese, P Raghupathy, R Lodha, Stephen D Walter
Abstract
Background: WHO-defined pneumonias, treated with antibiotics, are responsible for a significant proportion of childhood morbidity and mortality in the developing countries. Since substantial proportion pneumonias have a viral etiology, where children are more likely to present with wheeze, there is a concern that currently antibiotics are being over-prescribed for it. Hence the current trial was conducted with the objective to show the therapeutic equivalence of two treatments (placebo and amoxycillin) for children presenting with non-severe pneumonia with wheeze, who have persistent fast breathing after nebulisation with salbutamol, and have normal chest radiograph.
Methodology: This multi-centric, randomised placebo controlled double blind clinical trial intended to investigate equivalent efficacy of placebo and amoxicillin and was conducted in ambulatory care settings in eight government hospitals in India. Participants were children aged 2-59 months of age, who received either oral amoxycillin (31-54 mg/Kg/day, in three divided doses for three days) or placebo, and standard bronchodilator therapy. Primary outcome was clinical failure on or before day- 4.
Principal findings: We randomized 836 cases in placebo and 835 in amoxycillin group. Clinical failures occurred in 201 (24.0%) on placebo and 166 (19.9%) on amoxycillin (risk difference 4.2% in favour of antibiotic, 95% CI: 0.2 to 8.1). Adherence for both placebo and amoxycillin was >96% and 98.9% subjects were followed up on day- 4. Clinical failure was associated with (i) placebo treatment (adjusted OR = 1.28, 95% CI: 1.01 to1.62), (ii) excess respiratory rate of >10 breaths per minute (adjusted OR = 1.51, 95% CI: 1.19, 1.92), (iii) vomiting at enrolment (adjusted OR = 1.49, 95% CI: 1.13, 1.96), (iv) history of use of broncho-dilators (adjusted OR = 1.71, 95% CI: 1.30, 2.24) and (v) non-adherence (adjusted OR = 8.06, 95% CI: 4.36, 14.92).
Conclusions: Treating children with non-severe pneumonia and wheeze with a placebo is not equivalent to treatment with oral amoxycillin.
Trial registration: ClinicalTrials.gov NCT00407394.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Murray CLZ, Lopez AD. Mortality by cause for eight regions of the World Global burden of disease study. Lancet. 1997;349:1269–1276.
- Mulholland K. Magnitude of the problem of childhood pneumonia. Lancet. 1999;54:590–592.
- Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2:25–32.
- Kusel MM, De Klerk NH, Holt PG, Kebadze T, Johnston SL. Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: A birth cohort study. Pediatr Infect Dis J. 2006;25:680–686.
- Awasthi S ISCAP Group Study. Three-day versus five-day treatment with amoxycillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. BMJ. 2004;328:791.
- Qazi S Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxycillin for treatment of childhood pneumonia: A multicentre double-blind trial. Lancet. 2002;360:835–841.
- World Health Organization. Handbook of IMCI (Integrated Management of Childhood Illnesses. 2000. Available: http://202.54.104.236/intranet/eip/immunizationmanager/pdf/CAH_00_12_Ti_Contents.pdf. Accessed 2008 March 6.
- Sachdev HPS, Mahajan SC, Garg A. Improving Antibiotic and bronchodilator prescription in children presenting with difficult breathing: experience from an Urban Hospital in India. Indian Pediatr. 2001;38:827–838.
- Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol. 2007;46:947–954.
- World Health Organization. The management of acute respiratory infections in children. Practical guidelines for outpatient care. Geneva: World Health Organization; 1995. pp. 14–24.
- Chow S, Shao J. A note on statistical methods for assessing therapeutic equivalence. Controlled Clinical Trials. 2002;23:515–520.
- Straus WL, Qazi SA, Kundi Z, Nomani NK, Schwartz B. Antimicrobial resistance and clinical effectiveness of cotrimoxazole versus amoxycillin for pneumonia among children in Pakistan: A Randomised Controlled Trial. Lancet. 1998;352:270–274.
- Kallstrom TJ. Evidence based asthma management. Respir Care. 2004;49:783–792.
- Hazir T, Qazi S, Nisar YB, Ansari S, Maqbool S, et al. Assessment and management of children aged 1–59 months presenting with wheeze, fast breathing, and/or lower chest indrawing; results of a multi centre descriptive study in Pakistan. Arch Dis Child. 2004;89:1049–1054.
- Lazzaro T, Hogg G, Barnett P. Respiratory Syncitial Virus infection and recurrent wheeze/asthma in children under five years: an epidemiological survey. J Paediatr Child Health. 2007;43:29–33.
- Simoes EAF, Cherian T, Chow J, Shahid–Salles SA, Laxminarayan R, et al. “Acute Respiratory Infections in Children.” Disease Control Priorities in Developing Countries (2nd Edition) New York: Oxford University Press; 2006. pp. 483–498.
- Broor S, Parveen S, Bharaj P, Prasad VS, Srinivasulu KN, et al. A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India. PLoS ONE. 2007;2(6):e491 doi:10.1371/journal.pone.0000491. Accessed 2008 March 6.
Source: PubMed